The funding of biopharmaceutical research and development / David R. Williams.

Format:

Book

Author/Creator:

Williams, David R.

Series:

Woodhead Publishing series in biomedicine ; no. 43.

Woodhead publishing series in biomedicine ; number 43

Language:

English

Subjects (All):

Pharmaceutical industry--Finance.

Pharmaceutical industry.

Biopharmaceutics.

Physical Description:

1 online resource (xxxvii, 245 pages) : illustrations, maps.

Edition:

1st edition

Place of Publication:

Cambridge : Woodhead Publishing, 2013.

Language Note:

English

System Details:

text file

Summary:

The funding of biopharmaceutical research and development provides a comprehensive critical review of the funding of research and development (R&D) in the human biopharmaceutical market sector. It addresses both private and public funding sources available in the US and internationally. The biopharmaceutical market is among the most research-intensive market sectors globally. Clinical researchers face a multitude of public and private funding options with respect to bringing their idea or innovation to market. These funding options are continually changing and complex, and are expected to decr

Contents:

Cover; The funding of biopharmaceutical research and development; Copyright; Dedication; Contents; List of figures and tables; Glossary; Preface; About the author; 1. Introduction to the biopharmaceutical market; 1.1 Introduction; 1.2 Synopsis of the development of the biopharmaceutical market sector; 1.3 Global growth of research and biopharmaceuticals; 1.4 Biopharmaceutical and healthcare value chain; 1.5 Demand for biopharmaceuticals; 1.6 Approval process; 1.7 Generic medicines; 1.8 Pricing of drugs; 1.9 Summary; 1.10 References; 2. Synopsis of theories of the firm and valuation methods

2.1 Introduction2.2 The neoclassical perfect competition model; 2.3 Industrial organization economics; 2.4 Resource-based view of the firm; 2.5 Innovation and entrepreneurship; 2.6 Valuation; 2.7 Real options; 2.8 Final words on valuations; 2.9 Corporate control; 2.10 Summary; 2.11 References; 3. Innovation and the merging of the pharmaceutical and biotechnology industries; 3.1 Patents and patent protection; 3.2 Standards and S-curves; 3.3 Real options reasoning; 3.4 Proinnovation bias; 3.5 Summary; 3.6 References; 4. The funding of basic research and public-private partnerships

4.1 Introduction to research funding in the U.S.4.2 Research funding in the European Union; 4.3 Research funding in Asia; 4.4 Technology transfer; 4.5 Technology transfer offices; 4.6 Bioclusters; 4.7 Biocenters; 4.8 Spillovers and the diffusion of biopharmaceuticals; 4.9 Summary; 4.10 References; 5. Strategic alliances; 5.1 Introduction to strategic alliances; 5.2 Forms of strategic alliances; 5.3 Models of the management of multiple alliances; 5.4 Not all alliances are strategic; 5.5 Opportunism in strategic alliances; 5.6 Summary; 5.7 References; 6. Angel and venture capital

6.1 Introduction to angel investors and venture capital6.2 Venture capital staging; 6.3 Venture capital history; 6.4 Ownership structure; 6.5 Venture capital and the entrepreneur; 6.6 Venture capital around the world; 6.7 Summary; 6.8 References; 7. The initial public offering; 7.1 An introduction to the initial public offering; 7.2 A brief synopsis of the history of stock exchanges; 7.3 The IPO process in the United States; 7.4 IPOs around the U.S.; 7.5 Research and development expenditures and fi nancial condition; 7.6 IPO performance; 7.7 Venture capital involvement; 7.8 IPO as exit

7.9 IPO activity around the world7.10 Summary; 7.11 References; 8. Conclusion; 8.1 Reference; Index

Notes:

"ISSN: 2050-0289."

Includes bibliographical references and index.

Description based on print version record.

ISBN:

9781908818386

1908818387

OCLC:

879653104